Contact:
4008465777
-
About Us
News & Events
-
07-14
Tonghua Dongbao announces NMPA acceptance of its NDA application for Insulin Aspart 30 and 50 Injections
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) received the notification of acceptance from the National Medical Products Administration (NMPA) on the NDA application...
-
06-30
Tonghua Dongbao introduces two novel drugs to its endocrine product portfolio
On June 30, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao, introduced two novel gout (hyperuricemia) drugs - THDB130/THDB131...
-
06-28
Tonghua Dongbao gets the nod for clinical trials on world’s first triple SGLT1/SGLT2/DPP4 inhibitor
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”), received the notice...
-
06-28
Tonghua Dongbao wins the Best Public Service Award in the 10th Chinese Listed Companies Forum
On June 27, Tonghua Dongbao was announced as the winner of the Best Public Service Award in the 10th Chinese Listed Companies Forum.The Forum was co-sponsored by the Shanghai Committee of China...
-
06-10
Tonghua Dongbao announces NMPA acceptance of its NDA application for repaglinide tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) received the notification of acceptance from the National Medical Products Administration (NMPA) on the NDA application...
-
04-26
Tonghua Dongbao sees accelerated profit growth recording YoY increase of 21.33% in Q1 2021
On the evening of April 26, Tonghua Dongbao (SH.600867, hereinafter referred to as the "Company") released its quarterly report for Q1 2021. In Q1 2021, the Company recorded operating revenue of RMB 823 million...